Sobi™ Publishes the Report for the Third Quarter 2018

STOCKHOLM, Oct. 31, 2018

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74 per cent for the quarter, and gross margin amounted to 75 per cent.

Continued strong growth in Q3

• Total revenues of SEK 2,315 M (1,601) in Q3 and SEK 6,568 M (4,636) YTD(1)
• 45 per cent sales growth in the quarter compared with Q3 2017 (34 per cent at CER)
• EBITA increased 74 per cent to SEK 933 M (536) in Q3 and 85 per cent to SEK 2,655 M (1,434) YTD(1)
• Net cash position of SEK 2,483 M (1,472 as of 31 December 2017)
• Revenues for Elocta® and Alprolix® were SEK 873 M (417) and SEK 255 M (98) respectively for Q31
• Kineret® sales were SEK 347 M (272) in Q3, an increase of 28 per cent
• Orfadin® sales were up 8 per cent amounting to SEK 217 M (202) in Q3
• Sobi strengthened both the Specialty Care franchise and the US product portfolio by acquiring the global rights to emapalumab
• First patients dosed in the phase 1/2 study with SOBI003

(1)Revenues as well for EBITA were positively affected by SEK 56 M, in Q3 2018, related to adjusted pharmaceutical taxes in France from 2017, whereof SEK 52 M relates to Elocta.

Financial summary